452 related articles for article (PubMed ID: 21233400)
1. CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice.
Zoglmeier C; Bauer H; Noerenberg D; Wedekind G; Bittner P; Sandholzer N; Rapp M; Anz D; Endres S; Bourquin C
Clin Cancer Res; 2011 Apr; 17(7):1765-75. PubMed ID: 21233400
[TBL] [Abstract][Full Text] [Related]
2. Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development.
Greifenberg V; Ribechini E; Rössner S; Lutz MB
Eur J Immunol; 2009 Oct; 39(10):2865-76. PubMed ID: 19637228
[TBL] [Abstract][Full Text] [Related]
3. Cyclophosphamide-induced myeloid-derived suppressor cell population is immunosuppressive but not identical to myeloid-derived suppressor cells induced by growing TC-1 tumors.
Mikyšková R; Indrová M; Polláková V; Bieblová J; Símová J; Reiniš M
J Immunother; 2012 Jun; 35(5):374-84. PubMed ID: 22576342
[TBL] [Abstract][Full Text] [Related]
4. Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events.
Schouppe E; Mommer C; Movahedi K; Laoui D; Morias Y; Gysemans C; Luyckx A; De Baetselier P; Van Ginderachter JA
Eur J Immunol; 2013 Nov; 43(11):2930-42. PubMed ID: 23878002
[TBL] [Abstract][Full Text] [Related]
5. A new mechanism for blocking myeloid-derived suppressor cells by CpG.
Lechner MG; Epstein AL
Clin Cancer Res; 2011 Apr; 17(7):1645-8. PubMed ID: 21288925
[TBL] [Abstract][Full Text] [Related]
6. Myeloid suppressor cell depletion augments antitumor activity in lung cancer.
Srivastava MK; Zhu L; Harris-White M; Kar UK; Huang M; Johnson MF; Lee JM; Elashoff D; Strieter R; Dubinett S; Sharma S
PLoS One; 2012; 7(7):e40677. PubMed ID: 22815789
[TBL] [Abstract][Full Text] [Related]
7. Expansion of CD11b(+)Ly6G (+)Ly6C (int) cells driven by medroxyprogesterone acetate in mice bearing breast tumors restrains NK cell effector functions.
Spallanzani RG; Dalotto-Moreno T; Raffo Iraolagoitia XL; Ziblat A; Domaica CI; Avila DE; Rossi LE; Fuertes MB; Battistone MA; Rabinovich GA; Salatino M; Zwirner NW
Cancer Immunol Immunother; 2013 Dec; 62(12):1781-95. PubMed ID: 24114144
[TBL] [Abstract][Full Text] [Related]
8. Myeloid-derived suppressor cell functionality and interaction with Leishmania major parasites differ in C57BL/6 and BALB/c mice.
Schmid M; Zimara N; Wege AK; Ritter U
Eur J Immunol; 2014 Nov; 44(11):3295-306. PubMed ID: 25142017
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells.
Shirota Y; Shirota H; Klinman DM
J Immunol; 2012 Feb; 188(4):1592-9. PubMed ID: 22231700
[TBL] [Abstract][Full Text] [Related]
10. GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells.
Morales JK; Kmieciak M; Knutson KL; Bear HD; Manjili MH
Breast Cancer Res Treat; 2010 Aug; 123(1):39-49. PubMed ID: 19898981
[TBL] [Abstract][Full Text] [Related]
11. Vasoactive intestinal peptide induces CD14+HLA-DR‑/low myeloid-derived suppressor cells in gastric cancer.
Li G; Wu K; Tao K; Lu X; Ma J; Mao Z; Li H; Shi L; Li J; Niu Y; Xiang F; Wang G
Mol Med Rep; 2015 Jul; 12(1):760-8. PubMed ID: 25695487
[TBL] [Abstract][Full Text] [Related]
12. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1.
Li H; Han Y; Guo Q; Zhang M; Cao X
J Immunol; 2009 Jan; 182(1):240-9. PubMed ID: 19109155
[TBL] [Abstract][Full Text] [Related]
13. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.
Finke J; Ko J; Rini B; Rayman P; Ireland J; Cohen P
Int Immunopharmacol; 2011 Jul; 11(7):856-61. PubMed ID: 21315783
[TBL] [Abstract][Full Text] [Related]
14. Myeloid-derived suppressor cell function is reduced by Withaferin A, a potent and abundant component of Withania somnifera root extract.
Sinha P; Ostrand-Rosenberg S
Cancer Immunol Immunother; 2013 Nov; 62(11):1663-73. PubMed ID: 23982485
[TBL] [Abstract][Full Text] [Related]
15. Targeting immune suppressing myeloid-derived suppressor cells in oncology.
Kao J; Ko EC; Eisenstein S; Sikora AG; Fu S; Chen SH
Crit Rev Oncol Hematol; 2011 Jan; 77(1):12-9. PubMed ID: 20304669
[TBL] [Abstract][Full Text] [Related]
16. Phenotype and Function of Myeloid-Derived Suppressor Cells Induced by Porphyromonas gingivalis Infection.
Su L; Xu Q; Zhang P; Michalek SM; Katz J
Infect Immun; 2017 Aug; 85(8):. PubMed ID: 28533469
[No Abstract] [Full Text] [Related]
17. The anti-tumor effect of the quinoline-3-carboxamide tasquinimod: blockade of recruitment of CD11b(+) Ly6C(hi) cells to tumor tissue reduces tumor growth.
Deronic A; Tahvili S; Leanderson T; Ivars F
BMC Cancer; 2016 Jul; 16():440. PubMed ID: 27400708
[TBL] [Abstract][Full Text] [Related]
18. Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release.
Jayaraman P; Parikh F; Lopez-Rivera E; Hailemichael Y; Clark A; Ma G; Cannan D; Ramacher M; Kato M; Overwijk WW; Chen SH; Umansky VY; Sikora AG
J Immunol; 2012 Jun; 188(11):5365-76. PubMed ID: 22529296
[TBL] [Abstract][Full Text] [Related]
19. Myeloid-Derived Suppressor Cell Survival and Function Are Regulated by the Transcription Factor Nrf2.
Beury DW; Carter KA; Nelson C; Sinha P; Hanson E; Nyandjo M; Fitzgerald PJ; Majeed A; Wali N; Ostrand-Rosenberg S
J Immunol; 2016 Apr; 196(8):3470-8. PubMed ID: 26936880
[TBL] [Abstract][Full Text] [Related]
20. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF.
Dolcetti L; Peranzoni E; Ugel S; Marigo I; Fernandez Gomez A; Mesa C; Geilich M; Winkels G; Traggiai E; Casati A; Grassi F; Bronte V
Eur J Immunol; 2010 Jan; 40(1):22-35. PubMed ID: 19941314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
